Cited by 330Cancer survivorship and careBreast Cancer Treatment StudiesChildhood Cancer Survivors' Quality of Life

Breast Cancer Survivorship, Quality of Life, and Late Toxicities

Open access

Abstract

Breast cancer is the most frequent cancer in women: in 2018, almost two million cases have been diagnosed all over the world and it represents the principal cause of death from a neoplastic disease in women. In the past years, breast cancer prognosis has significantly improved over time: currently 5-year survival rates are in the range of 90%, and 10-year survival is about 80%. This improvement has been mostly observed in western countries, due to high coverage and compliance with screening programs, leading to early diagnosis, i.e., when the disease is at a subclinical level, and to an improvement in tumor molecular characterization and innovative systemic treatments. Yet the identification of different biological breast cancer subtypes prompted the development of innovative targeted agents and improved treatment personalization. On the other hand, longer survival rates and increasing proportions of cured patients require dedicated strategies to manage long-term sequelae of breast cancer treatments, with particular attention to quality of life. This review analyzes the most important issues, potentially occurring with cancer treatments, concerning long-term sequelae and quality of life, to define a global approach to breast cancer survivorship.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2020.00864

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Somatic side effects of therapy (e.g., neurotoxicity, cardiotoxicity, lymphoedema, pain) and increased tumour-related stress or mental illnesses (e.g., anxiety, depression) play a central role in follow-up care.

    “In addition to somatic side effects of the therapy, such as neurotoxicity and cardiotoxicity, lymphoedema or pain [6–8], increased tumour-related stress or mental illnesses such as anxiety and depression play a central role in follow-up care.”

    From The BrEasT cancer afTER-CARE (BETTER-CARE) programme to improve breast cancer follow-up: design and feasibility study results of a cluster-randomised complex intervention trial (2024) · cites this paper as [7]

    The Background and Conclusions (pages not provided) say that treatment sequelae require attention and resources in breast-cancer follow-up. The Cardiotoxicity After Adjuvant Therapy section identifies cardiotoxicity as an important late effect and recommends follow-up examinations. Our copy does not identify neurotoxicity, lymphoedema or pain as examples; the citation in the printed sentence is attached to the somatic-effects clause, not the subsequent anxiety-and-depression clause. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Nardin, S., Mora, E., Varughese, F. M., D'Avanzo, F., Vachanaram, A. R., Rossi, V., Saggia, C., Rubinelli, S., & Gennari, A.
Affiliations
  • Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
  • Azienda Ospedaliero Universitaria Maggiore della Carita (IT)
Corresponding author
Gennari, Alessandra
Venue
Frontiers in Oncology
Published
2020-06-16
Volume
10
Pages
864-864
ISSN
2234-943X (ISSN-L)
OpenAlex
W3036457113
Cited by
330
References
39
Citations by year
2026: 47 · 2025: 85 · 2024: 83 · 2023: 55 · 2022: 37 · 2021: 21 · 2020: 2
FWCI
3.09
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Associazione Italiana per la Ricerca sul Cancro
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Childhood Cancer Survivors' Quality of Life
Keywords
breast cancer survivorship, quality of life, late toxicity, breast cancer screening, breast cancer subtypes, targeted therapy, personalized treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review